摘要
目的测定2型糖尿病患者血清Visfatin浓度，同时观察罗格列酮对Visfatin的影响。方法33例磺脲类降糖药治疗未能达标的2型糖尿病患者（糖尿病组）加用罗格列酮（4mg／d）治疗12周，对照组（27例）与糖尿病组性别、年龄及体重指数（BMI）匹配。测定血清Visfatin、总胆固醇（TC）、三酰甘油（TG）、高密度脂蛋白一胆固醇（HDL-C）、低密度脂蛋白-胆固醇（LDL—C）、空腹胰岛素（FINS）、空腹血糖（FPG）、餐后2h血糖（2hPPG）；此外，糖尿病组治疗前后测定血游离脂肪酸（FFA）、高敏C-反应蛋白（hs—CRP）、糖化血红蛋白（GHbA1c）及腹部脂肪分布。结果糖尿病组Visfatin水平低于对照组[（24．53±9．22）μg/L比（53．10±27．00）μg／L，P〈0．01]；糖尿病组治疗前后Visfatin比较差异无统计学意义[（24．53±9．22）μg／L比（32．62±24．89）μg／L，P〉0．05]。简单相关分析表明，Visfatin分别与收缩压（r=-0．29，P=0．02）、FPG（r=-0．40，P=0．001）、2hPPG（r=-0．34，P=0．009）、LDL—C（r=0．26，P=0．049）、FFA（r=0．44，P=0．009）相关。多元回归分析发现，FFA是Visfatin（r^2=0．30，f=7．707，P=0．009）的独立相关因素。结论2型糖尿病患者血清Visfatin浓度明显降低，且与机体糖、脂代谢紊乱关系密切。短期罗格列酮治疗未明显升高2型糖尿病患者血清Visfatin浓度。
Objective To determine the serum level of Visfatin, and observe the effect of short-term treatment of resiglitazone on it in the patients with type 2 diabetes mellitus. Methods Thirty-three patients with type 2 diabetes mellitus（diabetic group） who were inadequately controlled by sulfonylureas were treated with rosiglitazone （4 rag/d） for 12 weeks. Twenty-seven sex-, age- and BMI-matched non-diabetic subjects （control group） were studied. Determined blood pressure, Visfatin, triglyceride （TG）, high density lipoprotein cholesterol （HDL-C）, low density lipoprotein cholesterol （LDL-C）, fasting plasma glucose （FPG）, 2-hour postprandial glucose （2 h PPG）, fasting insulin （FINS）in all subjects and free fatty acid （FFA）, high sensitive C-reactive protein （hs-CRP） and glycosylated hemoglobin （GHbA1c）, abdominal fat distribution before and after treatment with rosiglitazone in diabetic group respectively. Results The level of serum Visfatin was lower in diabetic group than that in control group [ （24.53 ±9.22） μg/L vs （53.10 ± 27.00） μg/L, P 〈 0.01 ], and it was higher after treatment with rosiglitazone for 12 weeks, but there was no significant difference [ （24.53 ± 9.22）μ g/L vs （32.62 ±24.89） μg/L, P 〉 0.05 ]. Visfatin was correlated significantly with systolic pressure （r = -0.29,P = 0.02）,FPG （r =-0.40, P = 0.001 ）, 2 h PPG （r =-0.34, P = 0.009）, LDL-C （r = 0.26,P = 0.049） and FFA （r = 0.44,P = 0.009） respectively. In a linear stepwise regression analysis, FFA showed significant correlation with serum Visfatin levels （r^2 = 0.30,f= 7.707, P = 0.009）. Conclusions The level of serum Visfatin is lower in type 2 diabetes mellitus, and it is related significantly with glucose and lipid metabolic factors. The short-term treatment with rosiglitazone can＇t increase the serum concentration of Visfatin in the type 2 diabetes mellitus.
出处
《中国医师进修杂志（内科版）》
2008年第11期24-27,共4页
Chinese Journal of Postgraduates of Medicine
